Replies to post #145767 on Biotech Values

[DewDiligence]

With annualized sales of >$1B, Gilenya is officially a blockbuster* already. Remarkably, the damage to Copaxone has been small (#msg-75932085); Gilenya is evidently taking most of its share from other MS drugs.

*I’m using the US definition rather than the European definition that has a threshold of €1B :- )

[DewDiligence]

Actually, US sales of Gilenya have nearly reached a plateau, rising only 6% YoY from $170M to $181M (http://www.novartis.com/downloads/investors/financial-results/quarterly-results/2012-07-interim-financial-report.pdf page 61); it’s the rapid growth internationally that has turned Gilenya into a $1B+ blockbuster.